Introduction
Accounting for 2-3% of all prolactin-secreting tumors, giant prolactinomas are rare [1] . Characterized as large, prolactin-producing tumors with diameters of 4 cm or more, these tumors present unique diagnostic challenges [1] . Unlike typical pituitary prolactinomas that tend to present with symptoms of hyper prolactinemia, giant prolactinomas may manifest as neurologic deficits due to pressure 
Pathologic Findings
The biopsy was labeled "left posterior nasal fossa" and consisted of multiple fragments of tissue measuring in aggregate 2.0 × 1.0 × 0.3 cm. Approximately 70% of the sample consisted of organizing hemorrhage, blood clots and infarcted tumor (Fig. 2a) . The residual viable tumor consisted of sheets of neoplastic cells with a rich vascular network. The individual neoplastic cells were relatively small, round and monotonous and exhibited scanty light eosinophilic cytoplasm and smooth round nuclei with absent nucleoli (Fig. 1b) . The mitotic rate was one mitotic figure per ten high-power fields (1 mf/10 hpf). The tumor cells were positive for low-molecular weight keratin and pankeratin (CAM5.2, AE1:AE3), synaptophysin, CD56, prolactin and Pit-1 (Fig. 3a-c) . Epithelial membrane antigen (EMA), chromogranin, estrogen receptors (ER), growth hormone (GR), thyroid stimulating hormone (TSH), S100, HMB45, CD45 and neurofilament (NF) were negative. 
Discussion
This case illustrates some of the diagnostic difficulties presented by neuroendocrine tumors in the base of the skull. The main pathologic differential diagnosis of neuroendocrine neoplasms in this region includes olfactory neuroblastoma (ONB), neuroendocrine carcinoma (NEC) and pituitary adenoma. Pituitary adenomas presenting in uncommon anatomic locations are commonly misdiagnosed [6] and similar cases of giant prolactinoma masquerading as skull base/nasal tumors have been described in the literature (Table 1) . Therefore, the immunohistochemical work-up of a well differentiated neuroendocrine neoplasm in the base of the skull should include pan-keratin, synaptophysin, chromogranin, CD56, S100 and depending on the combination of microscopic findings and initial immunohistochemical results, a panel of pituitary hormone markers and transcription factors such as prolactin and Pit-1. Certain microscopic findings such as the presence of intranuclear cytoplasmic inclusions, delicate fibrovascular stroma, variable growth pattern and plasmacytoid morphology could be helpful in raising the possibility of pituitary adenoma. Hemorrhage and necrosis do not exclude the diagnosis [6] . This patient's tumor showed some confounding features, such as being labeled "posterior fossa nasal tumor", lack of endocrine symptoms and extensive hemorrhage and infarction, which might have contributed to the initial misdiagnoses of ONB and NEC. With the increasing clinical manifestations of hyperprolactinemia and the addition of pituitary hormones markers, the revised diagnosis of lactotroph pituitary adenoma was readily established.
This case also illustrates that the imaging features of pituitary macroadenomas can be misleading if not clearly classical as seen to be centered on the sella and arising from an enlarged pituitary gland with more typical suprasellar extension. Upon review of original imaging, the infiltration of the lesion through the floor of the sella and into adjacent central bony skull base structures, submucosal nasopharyngeal tissues, sphenoid sinuses, as well as laterally into the cavernous sinuses, although rare, can be seen with pituitary tumors as ultimately, demonstrated in this case. The imaging appearance of an infiltrative central skull base tumor would include lymphoma, meningioma as well as carcinoma given submucosal nasopharyngeal and sphenoid sinus involvement.
There needs to be a high degree of suspicion for a diagnosis of pituitary adenomas in patients with base of skull lesions and atypical clinical courses, given the good prognosis and potential for significant clinical and serological response to first-line therapy with dopamine agonists such as Cabergoline [1] .
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